Business
Fennec Pharmaceuticals to Participate in the 2022 Maxim Virtual Growth Conference
RESEARCH TRIANGLE PARK, N.C., March 25, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company
About this update from Fennec Pharmaceuticals Inc.
[{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., March 25, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the Company will be participating in the 2022 Maxim Group Virtual Growth Conference, taking place March 28-30, 2022. The conference will feature company presentations, fireside chats, roundtable discussions, and live Q&A moderated by Maxim Research Analysts. Robert Andrade, Fennec’s Chief Financial Officer, will participate in a fireside chat on Monday, March 28, at 4:00 p.m. ET. This conference will be live on M-Vest. To view, Click Here to Reserve your seat or https://m-vest.com/events/2022-virtual-growth-conference. About PEDMARK™ Cisplatin and other platinum compounds are essential chemotherapeutic agents for many pediatric malignancies. Unfortunately, platinum-based therapies cause ototoxicity, or hearing loss, which is permanent, irreversible and particularly harmful to the survivors of pediatric cancer. In the U.S. and Europe, it is estimated that, annually, over 10,000 children may receive platinum-based chemotherapy. The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only expensive, technically difficult and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. Infants and young children that suffer ototoxicity at critical stages of development lack speech language development and literacy, and older children and adolescents lack social-emotional development and educational achievement. PEDMARK has been studied by cooperative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. Both studies have been completed. The COG ACCL0431 protocol enrolled childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with locali...